PAXLOVID

Copyright infringement not intended.

Context

• Pfizer announced trial results for its investigational Covid-19 oral antiviral candidate, Paxlovid, saying it significantly reduced hospitalisation and death.-why-is-google-doodle-celebrating-her-biceived ‘heaviest rainfall’ since 2015.

About

• It is an investigational SARS-CoV-2 “protease inhibitor antiviral therapy”.
• It inhibits viral replication at proteolysis, a stage that occurs before viral replication.
• It is “designed to be administered orally so that it can be prescribed at the first sign of infection or at first awareness of an exposure, potentially helping patients avoid severe illness.”
• Pfizer said it has entered into advance purchase agreements with “multiple countries and is in negotiations with several others”.

https://indianexpress.com/article/explained/explained-two-new-oral-drugs-and-the-treatment-of-covid-19-7611923/